<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076201</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A01248-49</org_study_id>
    <nct_id>NCT05076201</nct_id>
  </id_info>
  <brief_title>Process of Regulation in Addictions: Vulnerability Emotional Factors to Craving</brief_title>
  <acronym>Procrav</acronym>
  <official_title>Process of Regulation in Addictions: Vulnerability Emotional Factors to Craving</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ramsay santé</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to have a better understanding of the relationship between&#xD;
      self-controle difficulties (and more specifically the inhibition deficit in impulsivity),&#xD;
      emotional regulation disorders such as alexithymia and craving.This study will be the first&#xD;
      in France to specify the interactions between self-regulkation processes dysfunctions and&#xD;
      emotional dysfunctions in craving.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to measure the level of cocaine craving, 6 months after the end of&#xD;
      their detoxification treatment (outpatient or full hospitalization), in patients with a&#xD;
      diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to&#xD;
      alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief&#xD;
      will be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Actual">November 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaïne craving evaluation</measure>
    <time_frame>6 months</time_frame>
    <description>Using the French version of the questionnaire CCQ-Brief &quot;Cocaïne Craving Questionnaire&quot;.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Craving</condition>
  <condition>Emotional Dysfunction</condition>
  <condition>Self-Regulation, Emotion</condition>
  <condition>Alexithymia</condition>
  <condition>Cocaine Addict</condition>
  <arm_group>
    <arm_group_label>Patients with completed rehab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The aim of this research is to follow-up a cohort of patients at the end of their detoxification cure (cocaïne).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patients with completed rehab</intervention_name>
    <description>The main objective is to measure the level of cocaine craving, 6 months after the end of their detoxification treatment (outpatient or full hospitalization), in patients with a diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief will be used.</description>
    <arm_group_label>Patients with completed rehab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient, men or women between 18 and 60 years-old&#xD;
&#xD;
          -  Patient with a diagnosis of moderate to severe dependence (DSM 5) to cocaine with or&#xD;
             without co-addictions to alcohol or psychostimulant.&#xD;
&#xD;
          -  Patient on day-hospitalisation or full hospitalisation&#xD;
&#xD;
          -  Patient affiliated or beneficiary to a social security scheme.&#xD;
&#xD;
          -  Patient having signed the free and informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with psychiatric disorders psychosis type&#xD;
&#xD;
          -  Patient with severe chronic somatic disease.&#xD;
&#xD;
          -  Patient participating in another clinical study&#xD;
&#xD;
          -  Protected patient: adult under guardianship, curatorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision.&#xD;
&#xD;
          -  Pregnant, breastfeeding or parturient woman.&#xD;
&#xD;
          -  Patient hospitalized without consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François Oudet</last_name>
    <phone>06 83 34 65 67</phone>
    <email>jf.oudet@ecten.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Hélène Barba</last_name>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique privée</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Oudet</last_name>
      <email>jf.oudet@ecten.eu</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Hélène Barba</last_name>
      <email>mh.barba@ecten.eu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vulnerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Affective Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

